76 related articles for article (PubMed ID: 6733855)
1. Ovarian mesothelial tumors and herbicides: a case-control study.
Donna A; Betta PG; Robutti F; Crosignani P; Berrino F; Bellingeri D
Carcinogenesis; 1984 Jul; 5(7):941-2. PubMed ID: 6733855
[TBL] [Abstract][Full Text] [Related]
2. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
[TBL] [Abstract][Full Text] [Related]
3. Triazine herbicides and ovarian epithelial neoplasms.
Donna A; Crosignani P; Robutti F; Betta PG; Bocca R; Mariani N; Ferrario F; Fissi R; Berrino F
Scand J Work Environ Health; 1989 Feb; 15(1):47-53. PubMed ID: 2922589
[TBL] [Abstract][Full Text] [Related]
4. p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer.
Ito T; Hamasaki M; Matsumoto S; Hiroshima K; Tsujimura T; Kawai T; Shimao Y; Marutsuka K; Moriguchi S; Maruyama R; Miyamoto S; Nabeshima K
Am J Clin Pathol; 2015 Jun; 143(6):830-8. PubMed ID: 25972325
[TBL] [Abstract][Full Text] [Related]
5. Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma.
Davidson B; Skrede M; Silins I; Shih IeM; Trope CG; Flørenes VA
Cancer; 2007 Sep; 110(6):1264-71. PubMed ID: 17647260
[TBL] [Abstract][Full Text] [Related]
6. Malignant pleural mesothelioma: some aspects of epidemiology, differential diagnosis and prognosis. Histological and immunohistochemical evaluation and follow-up of mesotheliomas diagnosed from 1964 to January 1985.
Walz R; Koch HK
Pathol Res Pract; 1990 Feb; 186(1):124-34. PubMed ID: 1690413
[TBL] [Abstract][Full Text] [Related]
7. Consistent gene expression profiles in MexTAg transgenic mouse and wild type mouse asbestos-induced mesothelioma.
Robinson C; Dick IM; Wise MJ; Holloway A; Diyagama D; Robinson BW; Creaney J; Lake RA
BMC Cancer; 2015 Dec; 15():983. PubMed ID: 26680231
[TBL] [Abstract][Full Text] [Related]
8. ME1. A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies.
O'Hara CJ; Corson JM; Pinkus GS; Stahel RA
Am J Pathol; 1990 Feb; 136(2):421-8. PubMed ID: 2305835
[TBL] [Abstract][Full Text] [Related]
9. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
10. Use of a crop and job specific exposure matrix for estimating cumulative exposure to triazine herbicides among females in a case-control study in the Central Valley of California.
Young HA; Mills PK; Riordan D; Cress R
Occup Environ Med; 2004 Nov; 61(11):945-51. PubMed ID: 15477289
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal mesotheliomas induced in mice by a polycyclic aromatic hydrocarbon.
Rice JM; Kovatch RM; Anderson LM
J Toxicol Environ Health; 1989; 27(1):153-60. PubMed ID: 2724365
[TBL] [Abstract][Full Text] [Related]
12. Ovarian cancer risk and use of phenolphthalein-containing laxatives.
Cooper GS; Longnecker MP; Peters RK
Pharmacoepidemiol Drug Saf; 2004 Jan; 13(1):35-9. PubMed ID: 14971121
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of osteopontin in epithelioid mesotheliomas and reactive mesothelial proliferations.
Tigrani DY; Weydert JA
Am J Clin Pathol; 2007 Apr; 127(4):580-4. PubMed ID: 17369133
[TBL] [Abstract][Full Text] [Related]
14. Mesothelioma or ovarian carcinoma? A case report.
Falkson CI
S Afr Med J; 1985 Oct; 68(9):676-7. PubMed ID: 4060030
[TBL] [Abstract][Full Text] [Related]
15. Does exposure to asbestos cause ovarian cancer? A systematic literature review and meta-analysis.
Reid A; de Klerk N; Musk AW
Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1287-95. PubMed ID: 21610219
[TBL] [Abstract][Full Text] [Related]
16. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
17. So-called peritoneal implants of ovarian carcinomas. Problems in differential diagnosis.
Dienemann D; Pickartz H
Pathol Res Pract; 1987 Apr; 182(2):195-201. PubMed ID: 3601795
[TBL] [Abstract][Full Text] [Related]
18. Mesovarian leiomyomas in the rat.
Gopinath C; Gibson WA
Environ Health Perspect; 1987 Aug; 73():107-13. PubMed ID: 3665855
[TBL] [Abstract][Full Text] [Related]
19. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
[TBL] [Abstract][Full Text] [Related]
20. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma.
Andrici J; Jung J; Sheen A; D'Urso L; Sioson L; Pickett J; Parkhill TR; Verdonk B; Wardell KL; Singh A; Clarkson A; Watson N; Toon CW; Gill AJ
Hum Pathol; 2016 May; 51():9-15. PubMed ID: 27067777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
